文献速递新发突发、热带与寄生虫病

疾病传播对时间聚合疗效估计的影响:RTS,S与R21疟疾疫苗III期试验因素分析

The effect of disease transmission on time-aggregated treatment efficacy estimates: a critical analysis of factors influencing the RTS,S and R21 malaria vaccine phase 3 trials.
PubMed 文献 · Lancet Infect Dis · 2025-04-23

本文为Personal View,综述临床试验中影响疗效估计的非生物学因素,重点讨论疫苗保护力衰减与传播强度随时间变化的交互作用。利用R21与RTS,S已发表的III期试验结果,作者展示该效应并可致不同接种日期下疫苗疗效相差10%至20%,并提出分析与报告建议。

要点

  • R21与RTS,S首年随访对多个临床疟疾发作的疗效分别为72%(95%CI 69-76)与55%(51-59)。
  • 疫苗保护力随时间衰减与传播强度变化(季节性、暴发传播、年龄相关易感性)交互,影响时间聚合疗效估计。
  • 该效应可干扰保护性疗效决定因素的识别,作者提出分析与报告建议。

核心结论

  • 临床试验疗效结果不仅反映干预的个体生物学保护,还受随访期疾病传播强度与分布影响。
  • 当疗效随时间变化(如R21与RTS,S的保护力衰减),传播变化可使随访某些时段对总体估计贡献更大,导致实际预防水平出现真实差异。
  • 利用已发表的R21与RTS,S试验结果,作者展示该效应并给出反事实预测,提示部分情形下不同接种日期疫苗疗效可能相差10%至20%。

研究设计与样本

  • Personal View(个人观点文章),非系统综述,未报告检索范围与样本量。
  • 基于R21与RTS,S已发表的儿科III期临床试验结果进行分析与反事实预测。
  • 回顾可影响临床试验疗效估计的所有非生物学因素,重点为疫苗保护力衰减与传播强度随时间变化的交互作用。

主要发现

  • 非洲儿科III期试验中,R21与RTS,S首年随访对多个临床疟疾发作的疗效分别为72%(95%CI 69-76)与55%(51-59)。
  • R21在季节性传播地区疗效更高;RTS,S在11个非洲试验点间疗效差异明显,原文称尚无明确解释。
  • 不同接种日期下疫苗疗效部分情形可能相差10%至20%(反事实预测)。

临床怎么用

  • 作者提示,分析与报告试验结果时应考虑传播强度随时间变化与疫苗保护力衰减的交互作用。
  • 作者就该效应提出在试验结果分析与报告中的应对建议(原文未给出具体条款与等级)。
  • 原文指出这些疗效估计被用于制定公共卫生政策与产生新的研究假设。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Comparing the efficacy of preventive interventions against infectious diseases, such as vaccines, across different field clinical trials or between subpopulations within the same trial, is common practice. In the case of malaria, WHO has approved two biosimilar subunit vaccines in the past 3 years, both targeting the circumsporozoite protein of the Plasmodium falciparum parasite for mass vaccination. In paediatric phase 3 clinical trials in Africa, the R21 and RTS,S vaccines showed efficacies of 72% (95% CI 69-76) and 55% (51-59) against multiple episodes of clinical malaria in the first year of follow-up, respectively. Notably, R21 exhibited higher efficacy in seasonal transmission areas, whereas RTS,S showed substantial variation in efficacy across the 11 African trial sites, with no clear explanation for this heterogeneity. These efficacy estimates are used to inform public health policies and generate new research hypotheses. However, the fact that efficacy results from clinical trials reflect more than the individual biological protection provided by a treatment, and are also influenced by the intensity and distribution of disease transmission during the follow-up period, is often overlooked. In this Personal View, we review all non-biological factors that can affect efficacy estimates in clinical trials, and particularly focus on one factor that has received little attention despite its importance and ease of identification: the interaction of waning vaccine protection with changes in transmission intensity over time. When efficacy varies over time, typically in the form of waning protection as is the case for R21 and RTS,S efficacy, variations in disease transmission, such as those due to seasonality, outbreak spread, or age-related susceptibility, can cause some periods of the follow-up to have a stronger contribution to the overall estimate than others. This interaction results in real differences in the level of disease prevention achieved, which in turn affects all commonly reported time-aggregated efficacy estimates. Using published results from R21 and RTS,S trials, we show this effect and provide a series of counterfactual predictions, illustrating how vaccine efficacy might differ, by between 10% and 20% in some cases, under alternative vaccination dates. We also discuss how this effect might confound efforts to identify determinants of protective efficacy and offer recommendations to address it in the analysis and reporting of trial results.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Macià D, Pons-Salort M, Moncunill G, et al. The effect of disease transmission on time-aggregated treatment efficacy estimates: a critical analysis of factors influencing the RTS,S and R21 malaria vaccine phase 3 trials. Lancet Infect Dis. 2025. PMID: 40286802. doi:10.1016/S1473-3099(25)00090-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。